The overall goal for this meeting is to bring together scientific leaders and trainees with a common interest in PI3Ks and relevant downstream physiological processes. It will address advances in basic molecular and cellular mechanisms that are regulated by PI3Ks, other PI kinases and, their cognate phosphatases; highlight new advances in the characterization of PI3K pathway alterations in genetic syndromes that affect growth and the immune and nervous systems; and provide an important update on the clinical development of PI3K pathway inhibitors, and implications for the burgeoning field of cancer immunotherapy. Whole exome sequencing studies have increasingly implicated PI3K signaling in diseases (immune, growth and neurological disorders) which may benefit from drugs currently in development for cancer and inflammation. This meeting will be an important forum for discussing approaches to treating these additional disorders.
- Lead institution: Scientific Organizers: Leon O. Murphy, Klaus Okkenhaug and Sabina C. Cosulich
- Date: January 19—23, 2017
- Place: Hilton Santa Fe Historic Plaza Hotel, Santa Fe, New Mexico, USA